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Abstract
Objectives: The Complex Regional Pain Syndrome I
(CRPS I) is a disease that might affect an extremity af-
ter trauma or operation. The pathogenesis remains yet
unclear. It has clinical signs of severe local inflamma-
tion as a result of an exaggerated inflammatory re-
sponse but neurogenic dysregulation also contributes
to it. Some studies investigated the role inflammatory
mediators and cytokines; however, few longitudinal
studies exist and control groups except healthy con-
trols were not investigated yet.
Methods: To get further insights into the role of sys-
temic inflammatory mediators in CRPS I, we investi-
gated a variety of pro-, anti-, or neuro-inflammatory
mediators such as C-Reactive Protein (CRP), White
Blood Cell Count (WBC), Interleukins 4, 6, 8, 10, 11,
12 (p70), Interferon gamma, Tumor-Necrosis-Factor
alpha (TNF-α) and its soluble Receptors I/II, soluble
Selectins (E,L,P), Substance-P (SP), and Calcitonin
Gene-Related Peptide (CGRP) at different time points
in venous blood from patients with acute (AC) and
chronic (CC) CRPS I, patients with forearm fractures
(FR), with neuralgia (NE), and from healthy volun-
teers (C).
Results: No significant changes for serum parameters
investigated in CRPS compared to control groups
were found except for CC/C (CGRP p = 0.007),
F R / C( C G R Pp=0 . 0 4 8 )a n dA C / C C( I L - 1 2p=0 . 0 2 ;
TNFRI/II p = 0.01; SP p = 0.049). High interindivid-
ual variations were observed. No intra- or interindivid-
ual correlation of parameters with clinical course (e.g.
chronification) or outcome was detectable.
Conclusion: Although clinically appearing as inflamma-
tion in acute stages, local rather than systemic inflam-
matory responses seem to be relevant in CRPS. Vari-
able results from different studies might be explained
by unpredictable intermittent release of mediators
from local inflammatory processes into the blood
combined with high interindividual variabilities. A
clinically relevant difference to various control groups
was not notable in this pilot study. Determination of
systemic inflammatory parameters is not yet helpful in
diagnostic and follow-up of CRPS I
Key words: CRPS-I, Reflex dystrophy, Inflammation,
Cytokines
INTRODUCTION
The Complex Regional Pain Syndrome type I is a
frequent complication in surgical patients after trauma
or operation on an extremity. It is characterized by dis-
proportionate pain, allodynia, vasomotor changes, de-
creased range of motion and edema in the affected
limb [1]. Prospective studies in patients with distal ra-
dial fractures showed an incidence of CRPS I up to
20% [2, 3].
Although the clinical picture and epidemiology of
CRPS I are well known, the underlying pathophysiolo-
gy remains unclear.
Diverse explanations exist for the pathogenesis in-
cluding abnormal function of the central nervous sys-
tem [4, 5], increased efferent sympathetic response fol-
lowing injury [6, 7], upregulated alpha-adrenoreceptors
[8], oxidative stress [9], or an excessive neuro-inflam-
matory response [10, 11].
In a previous study we demonstrated that in pa-
tients with CRPS I several changes in systemic inflam-
matory mediators can be noted [12]. However, in this
study as in several others [10, 11, 13], no control
groups other than healthy volunteers were used. In ad-
dition no longitudinal investigations exist for systemic
inflammatory parameters.
Thus the objective of our study was to further eluci-
date whether inflammatory mediators are involved in
the pathogenesis of CRPS I by multidirectional analysis
of inflammatory and neuro-inflammatory mediators in
plasma of patients presenting signs of acute or chronic
CRPSIcomparedtohealthy controls, patients with neur-
algia, or forearm fractures in a longitudinal manner.
MATERIALS AND METHODS
Twenty-two patients (15 females and 7 males) with a
mean age of 47 years (range 29-82 years) with clinical-
ly diagnosed acute or chronic CRPS I of an upper
limb were examined between May 2003 and May 2004
at the Division of Paintherapy, Department of Anes-
thesiology, and the Department of Surgery, University
Hospital Bergmannsheil, Ruhr-University, Bochum,
Germany. Within this group 12 patients presented
with a chronic form (6 female, 6 male, 47 yrs. (29-82
yrs.)) and 10 patients with acute forms (9 female, 1
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volunteers (4 female, 4 male, 41 yrs. (25-52 yrs.)), 5 pa-
tients with forearm fractures (1 female, 4 male, 48 yrs.
(18-78 yrs.)), and 4 patients with neuralgia (1 female, 3
male, 31-61 yrs.)) were included.
The diagnosis of CRPS I was established using the
criteria of the 1993 Consensus Conference of the In-
ternational Association for the study of Pain [1] as
well as the advanced differentiating criteria published
by Brühl et al. [14].
All but one patient in each CRPS I group presented
with a positive bone scintigraphy.
The groups investigated were prospectively defined
(Table 1).
In all patients with CRPS I, the disease was triggered
by an operation or injury of the hand or wrist. 20 pa-
tients were initially treated because of fracture or soft
tissue trauma at the hand or wrist. Other causes for
similar clinical signs other than CRPS were excluded
such as evidence of infection or delayed bone healing.
All patients were detected during follow-up visits
after trauma or operation or were transferred from
other hospitals. Patients with evidence of CRPS I were
diagnosed and treated by an interdisciplinary group of
surgeons, neurologists, physiotherapists, and anesthe-
siologists.
None of the patients and controls had any evidence
of other inflammatory diseases or immunosuppres-
sion. Diabetes, arteriosclerosis, Raynaud syndrome,
smoker (>20 cigarettes/day), or peripheral polyneu-
ropathy were also exclusion criteria.
All patients received standardized pain management
(World Health Organization (WHO) protocols I/II)
consisting of non-steroidal anti-inflammatory drugs,
metamizol, or opiates according to their pain levels.
Informed consent was obtained from the patients
and the study was approved by the ethical committee
of the medical school of the Ruhr-University Bochum.
The clinical monitoring consisted in a standardized
past medical history questionnaire (DGSS Question-
naire), clinical evaluation and a minimum follow-up of
6 months.
After clinical examinations venous blood was drawn
from the affected arm by puncture of ante-cubital vein
with standard cannulas without application of a tourni-
quet.
White blood cell counts and C-Reactive Protein
measurements were performed in the clinical routine
laboratory of the hospital. Five milliliters EDTA blood
were centrifuged at 3000 RPM for 10 minutes and
aliquots of plasma supernatants were stored at -80° C.
The following parameters (Table 2) were deter-
mined in plasma samples at certain time points (Table
3) using ELISA techniques with commercial kits from
R&D Systems (Wiesbaden, Germany) according to the
manufacturer protocol.
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Table 1. Groups investigated.
Acute CRPS I Chronic CRPS I Neuralgia Fracture Healthy controls
(AC) (CC) (NE) (FR) (C)
clinical criteria of IASP clinical criteria of IASP injury of peripheral hand-/ distal forearm
nerves with persisting fractures
pain
acute stage; <6 months > 6 and <12 months 5-6 weeks after injury
Table 2. Parameters investigated.
Cytokines and Receptors Neuropeptides Soluble Selectins
Interleukin 4 (IL-4) Substance P (SP) Soluble E-Selectin (sE-Selectin)
IL-6 Calcitonin Gene-Related- sL-Selectin
Peptide (CGRP)
IL-8 sP-Selectin
IL-10
IL-11
IL-12(p70)
Tumor Necrosis Factor
alpha (TNF-α)
Soluble TNF Receptor I
and II (sTNFRI/II)
Interferon gamma (IFN-γ)
Table 3. Time points of investigations.
Acute CRPS I Chronic CRPS I Neuralgia Fracture Healthy controls
week 0, 1, 2, 4, 6, 12 week 0, 12, 24 week 1-6 week 5-6 after trauma week 1STATISTICAL ANALYSIS
Since normality testing failed using the Kolmogorov-
Smirnov test, the non-parametric Mann-Whitney-U-
Test was used to compare plasma samples of the pa-
tients with those of the control groups. Data are
shown as median and range. A p-value < 0.05 was ac-
cepted to be significant (*).
RESULTS
Interleukin 4:
IL-4 was 17.2 pg/ml (6-87 pg/ml) in healthy volun-
teers. There were no significant differences to AC
(18.0 pg/ml (0-376 pg/ml)), CC (25.4 pg/ml (8-91
pg/ml)), NE (17.9 pg/ml (12-44 pg/ml), or FR (25.8
pg/ml (13-54 pg/ml)). There was no detectable trend
within the clinical course of AC or CC but high intra-
and interindividual variations were observed.
Interleukin 6:
All groups investigated remained close to the control
median of 9.5 pg/ml (8-184 pg/ml)). AC: 9 pg/ml (2-
190 pg/ml); CC: 10 pg/ml (3-46 pg/ml)); NE: 12
p g / m l( 1 0 - 1 6p g / m l ) ;F R :9p g / m l( 8 - 1 9p g / m l ) ) .N o
trend was seen within group AC or CC.
Interleukin 8:
IL-8 was not detectable in most samples. In group C
and FR it was never detected (0 pg/ml), in AC 1pg/ml
( 0 - 6p g / m l ) ,i nC C0p g / m l( 0 - 9p g / m l ) ,a n di nN E0
pg/ml (0-1 pg/ml).
Interleukin 10:
IL-10 was elevated in group FR compared to C (16.1
pg/ml (9-17 pg/ml) vs. 4.0 pg/ml (1-60 pg/ml)) but
the difference was not significant. Group AC (5.5
pg/ml (0-246 pg/ml), CC (7.6 pg/ml (0-36 pg/ml)),
and NE (7.7 pg/ml (2-248 pg/ml)) remained in be-
tween. High interindividual variations were shown but
t h e r ew a sn ot r e n do v e rt i m e .
Interleukin 11:
Whereas AC, CC, and FR remained for median and
range almost identical with C (0.5 pg/ml (0-74 pg/ml),
patients from group NE showed higher values (26.1
pg/ml (0-211 pg/ml). However, this trend was not sig-
nificant due to high interindividual variations.
Interleukin 12 (p70):
Despite the fact that all groups showed a median of
only 0 to 1 pg/ml, groups AC (1 pg/ml (0-352
pg/ml)) versus CC (0 pg/ml (0-141 pg/ml)) were sig-
nificantly different (p = 0.02) but only if all different
time points were added and in no case for a single in-
dividual. IL-12 (p70) was never detected in group FR.
Group C (1 pg/ml (0-33 pg/ml)) was not different to
patients. No relevant changes over time were demon-
strable.
Tumor Necrosis Factors alpha:
TNF plasma levels remained close to C values (12
pg/ml (4-69 pg/ml)) without any trend over time or
within the different groups.
Interferon gamma:
All patient groups showed lower values than healthy
controls (C: 11.4 pg/ml (0-570 pg/ml); AC 7.0 pg/ml
(0-1946 pg/ml); CC 0.4 pg/ml (0-2982 pg/ml); NE
(2.1 pg/ml (0-143 pg/ml); FR 0.6 pg/ml (0-4254
pg/ml)), but these differences did not reach signifi-
cance due to very high interindividual variations.
No correlation with clinical course was found for AC
orCC.
Soluble Selectins:
All three groups of soluble selectine (sE, sP, sL) re-
mained very close to healthy controls (sE: 1.9 pg/ml
(1.1-54 pg/ml); sP: 0.8 pg/ml (0.7-1.1 pg/ml); sL:
23.3 pg/ml (19.5-24.6 pg/ml) without high inter-
individual variations or changes over the observation
period.
Soluble TNF Receptors I/II:
For both receptors all groups remained close to C (I:
87 pg/ml (63-105 pg/ml); II: 343 pg/ml (312-340
pg/ml). Despite this fact a significant difference was
calculated between AC and CC (I: 85 pg/ml (62-129
pg/ml) vs. 73 pg/ml (40-132 pg/ml); II: 377 pg/ml
(264-497 pg/ml) vs. 322 pg/ml (152-463 pg/ml); p =
0.01) for all values taken together but not for individ-
ual patients or different time points. No relevant
changes over the time course were seen.
Substance P:
All groups showed higher levels of sP compared to C
(35 pg/ml (1-72 pg/ml) with a maximum in NE
patients (69 pg/ml (4-87 pg/ml)) without reaching
statistical significance. In contrast AC versus
CC was significant when all days were combined
(43.4 pg/ml (0-67 pg/ml) vs. 48.3 pg/ml (1-490
p g / m l ) ;p=0 . 0 4 9 )b u tw i t hb r o a di n t e r i n d i v i d u a l
variations and without any relevant changes over time
(Fig. 1).
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Fig. 1. In acute CRPS I (AC; grey bars) Substance P was sig-
nificant lower than in chronic forms (CC, white bars) but not
than healthy controls (C). A significance was reached only
when all days were combined (p = 0.049). High interindivid-
ual variations are shown and no relevant changes over time
were observed.Calcitonin-Gene-Related-Peptide:
Finally CGRP revealed some significant differences
between C (15.5 pg/ml (9-21 pg/ml)) and FR (6.0
pg/ml (3-16 pg/ml); p = 0.048) or CC (6.5 pg/ml (2-
32 pg/ml); p = 0.007) but also for week 12 and 24
alone (p<0.05). A high interindividual variation was
seen for AC with 13 pg/ml (2-590 pg/ml). No correla-
tion was found for clinical course and CGRP (Fig. 2).
White blood cell counts and C-Reactive Protein:
All groups remained within the normal value range of
4-11 G/l for WBC counts and below 1.2 mg/dl for
CRP. No relevant trends were found.
DISCUSSION
The clinical picture and epidemiology of Complex re-
gional pain syndromes (CRPS, formerly reflex sympa-
thetic dystrophy and causalgia) are well known but the
underlying pathophysiology remains unclear.
CRPS is characterized by neuropathic pain in one
extremity after a trauma. The initiating trauma affects
primarily the extremity, but can also be a central lesion
(e.g., spinal cord injury, stroke). CRPS is characterized
by sensory, autonomic and motor disturbances.
Pathophysiologically there are functional changes
within the central nervous system and involvement of
peripheral inflammatory processes. The sympathetic
nervous system plays a key role in maintaining pain
and autonomic dysfunction in the affected extremity.
[6, 15] After a primary central lesion, secondary pe-
ripheral changes in the paretic extremity are suggested
to be important in initiating CRPS [4, 5].
Most physicians believe this syndrome is initiated
by a hyperactive sympathetic system. However, various
studies question this mechanism [11, 16, 17].
From a surgeons view point the affected limb in
the acute stage of CRPS I looks inflamed, is edema-
tous, pinkish-blue or red, and warm. It has impaired
function. In contrast to generalized inflammation
such as SIRS or sepsis, patients with CRPS I are in
good general health without malaise. In 1942 the Ger-
man surgeon Paul Sudeck was the first to hypothesize
that a regional inflammatory response to injury might
be the cause of this syndrome (Sudeck´s Atrophy)
[18].
It was shown previously that macro- and microcir-
culatory changes in the CRPS I affected arm resemble
the systemic changes in patients with SIRS or sepsis
[19, 20, 21]. Those findings suggest that the profound
changes in both macro- and microvascular perfusion
in the CRPS I affected arm contribute to edema for-
mation and support the hypothesis of an inflammato-
ry associated pathogenesis of CRPS. Several small
studies suggest possible efficacy of antiinflammatories
for some of the symptoms of CRPS I [9, 22].
Supporting the theory of a localized inflammatory
process white blood cell counts, CRP and IL-6 were
not altered in the affected arm or in controls. The liver
as the major source of IL-6 and CRP and the central
immune organ in systemic inflammatory responses
does not seem to be involved in this disease.
In contrast to our previous study in acute CRPS I
with single time point investigation we could find only
distinct elevations of sP and TNFRI/II again, but not
of IL-8. The suppression of soluble selectins was not
shown again in this study [12].
Calcitonin Gene-Related Peptide was not altered in
our previous study but this recent study has demon-
strated some significant differences for CGRP such as
between controls and patients after fractures or with
chronic CRPS I. However those changes were margin-
al.
A n o t h e rs t u d yi n6 1p a t i e n t sw i t hr e f l e xd y s t r o p h y
demonstrated also a significant induction of systemic
CGRP and bradykinin levels. The authors speculate
that these mediators contribute to hyperalgesia, in-
flammation and motor alterations in these patients
[23].
Uceyler and colleagues have recently published a
study with 40 patients where elevated TNF-α plasma
levels and increased IL-2 messenger ribosomal nu-
clear acid (mRNA) values were found. Anti-inflamma-
tory cytokine mRNA such as IL-4 or IL-10 were sig-
nificantly suppressed [13].
In contrast, various trials have found no systemic
involvement. Increased serum levels might be due to
an inconsistent spill over from the local inflammatory
focus [24, 25, 26] and might explain controversial data
from Huygen et al. [27] who could not demonstrate
changes of IL-6, IL-1β, TNF-alpha, Neuropeptide Y
(NPY), and CRGP in serum during intermediate or
acute forms of CRPS I.
Van de Beek et al. also found no difference in sev-
eral cytokines (IL-1b, IL-6, IL-8, TNF-α,I L - 1 r a ,I L -
10) between CRPS I patients and healthy controls in a
study where the mean duration of the disease was 10
years [28]. It is likely that patients with long lasting
CRPS I develop central mechanisms that lead to the
chronification at least of the sensory symptoms rather
than a persistent inflammation [29].
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Fig. 2. Calcitonin-Gene-Related-Peptide revealed significant
differences between Controls (C) and Fractures (FR) or over-
all chronic CRPS (CC)(p = 0.007) but also for week 12 and
24 in group CC alone (p<0.05). A high interindividual varia-
tion was demonstrated. No trend was observed during clini-
cal course.Up to now the results on systemic inflammatory
cytokine responses are very inconsistent and vary
between the different study populations and settings.
High intra- and interindividual variations were shown
in our studies. There is no clinical relevance proven
so far that measurement of plasma cytokines is
helpful in diagnostic or follow-up of patients with
CRPS I.
The cause for the different results for the neuroin-
flammatory mediators remains unclear too. Different
definitions and terminology of the syndrome in com-
bination with different states of disease (chronic ver-
sus acute) and time points investigated might explain
these divergences.
Weber et al. have shown that in CRPS I patients a
severe plasma protein extravasation after strong tran-
scutaneous electrical stimulation and this reaction
could also be induced by the application of exogenous
Substance P [30].
Gradl and colleagues have recently published data
from an interventional animal model in which contin-
uous intra-arterial application of SP induced signs and
symptoms of CRPS such as edema, inflammation and
pain in rats. Under fluorescence microscopy enhanced
leukocyte-endothelial interaction was shown but no in-
crease in apoptosis.
This study indicates that SP is responsible for neu-
rogenic inflammation resulting in CRPS I-like symp-
toms even if some clinical signs such as thermal allo-
dynia were not present [31].
Those data are important to further elucidate the
mechanisms involved and might be the fundament
for further treatment studies. However, further stud-
ies might elucidate their role in the pathophysiology
of CRPS I. Any clinical use cannot yet be recom-
mended.
In contrast determination of cytokines in local arti-
ficial suction blisters on the affected arm of patients
with acute CRPS I seem to result in more consistent
data such as high levels of IL-6 and TNF [27], sup-
porting the theory that CRPS I is associated with a lo-
cal inflammatory pathogenesis.
Munnikes and Groeneweg from the group of Huy-
gen have published recently two studies on inflamma-
tory mediators in artificial suction blisters in interme-
diate stages of CRPS I [32, 33]. Again IL-6 and TNF-
α were significantly increased in the suction blisters on
the affected site despite significant improvement of
symptoms and pain compared to the acute stage. The
persistence of high inflammatory mediators locally ex-
cludes the use of cytokine monitoring for follow-up at
the recent time. However, involvement of inflamma-
tory mediators, vasoactive substances such as En-
dothelin-1 or Nitric oxide seem to be proven now in
various study settings.
In another study of this group using again their
suction blister model they found 10 representative cy-
tokines out of 25 investigated using a multiplex bead
array assay [34].
Further studies that will include control groups
such as patients with fracture or with neuropathic pain
have to elucidate more precise inflammatory mediator
profiles to differentiate those various forms of acute
or chronic local inflammation.
CONCLUSION
Acute forms of Complex Regional Pain Syndrome I
show clinically signs of inflammation. The pathogene-
sis is still not clear.
Recent studies have proven local involvement of in-
flammatory mediators, where as systemic responses
are very inconsistent which might be due to irregular
occurring systemic overspill of local mediators. A
clear correlation between acute or chronic stages of
disease and systemic inflammatory mediators is not
yet shown. This holds true especially if those groups
are compared to healthy controls, patients with fore-
arm fractures or neuralgia.
Further studies on local inflammatory responses
will elucidate the role of inflammatory components in
the pathogenesis of CRPS I. Additional larger longitu-
dinal studies in patients and relevant control groups
are warranted before any clinical use for diagnostics or
follow-up can be recommended.
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